Clinical utility of adjunctive retigabine in partial onset seizures in adults

Therapeutics and Clinical Risk Management

Volumn 8, Issue , 2012, Pages 7-14

  Rejdak, Konrad ^a   Luszczki, Jarogniew J ^a,b   Błaszczyk, Barbara ^c   Chwedorowicz, Roman ^b   Czuczwar, Stanislaw J ^a,b  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^b INSTITUTE OF AGRICULTURAL MEDICINE   (Poland)

^c High School of Economics and Law   (Poland)

Author keywords

Antiepileptic drugs; Epilepsy; Seizure control

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; ANTICONVULSIVE AGENT; BENZODIAZEPINE RECEPTOR; CARBAMAZEPINE; COCAINE; DIAZEPAM; FELBAMATE; LAMOTRIGINE; METHYLPHENIDATE; PHENCYCLIDINE; PHENOBARBITAL; PHENYTOIN; PLACEBO; POTASSIUM CHANNEL; POTASSIUM CHANNEL KCNQ4; POTASSIUM CHANNEL KCNQ5; POTASSIUM CHANNEL KV7.2; POTASSIUM CHANNEL KV7.3; RETIGABINE; TOPIRAMATE; UNCLASSIFIED DRUG; VALPROIC ACID;

ABNORMAL THINKING; ALZHEIMER DISEASE; AMNESIA; ANTICONVULSANT ACTIVITY; ANTICONVULSANT THERAPY; ARTICLE; ATAXIA; BLURRED VISION; CONFORMATIONAL TRANSITION; CONFUSION; DIPLOPIA; DISEASE COURSE; DIZZINESS; DOSE RESPONSE; DRUG ACETYLATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG GLUCURONIDATION; DRUG HALF LIFE; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG INHIBITION; DRUG METABOLISM; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG URINE LEVEL; DYSARTHRIA; FATIGUE; FOCAL EPILEPSY; GAIT DISORDER; HUMAN; IN VIVO STUDY; INTENTION TO TREAT ANALYSIS; MAINTENANCE THERAPY; MIGRAINE; MOOD DISORDER; NEUROPATHIC PAIN; NONHUMAN; PARESTHESIA; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PLASMA CONCENTRATION-TIME CURVE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESTLESS LEGS SYNDROME; SINGLE DRUG DOSE; SOMNOLENCE; SPASTICITY; SPEECH DISORDER; STROKE; TERATOGENESIS; TREATMENT DURATION; TREMOR; URINARY EXCRETION; URINARY TRACT INFECTION; VERTIGO;

EID: 84857081441     PISSN: 11766336     EISSN: 1178203X     Source Type: Journal    
DOI: 10.2147/TCRM.S22605     Document Type: Article

References (79)

1. Czuczwar SJ, Patsalos PN. The new generation of GABA enhancers. Potential in the treatment of epilepsy. CNS Drugs. 2001;15(5):339-350.
2. Czapinski P, Blaszczyk B, Czuczwar SJ. Mechanism of action of antiepileptic drugs. Curr Top Med Chem. 2005;5(1):3-14.
3. Czuczwar SJ, Trojnar MK, Gergont A, Kroczka S, Kacinski M. Stiripentol - characteristic of a new antiepileptic drug. Expert Opin Drug Discov. 2008;5(2):453-460.
4. Lee CY, Fu WM, Chen CC, Su MJ, Liou HH. Lamotrigine inhibits postsynaptic AMPA receptor and glutamate release in the dentate gyrus. Epilepsia. 2008;49(5):888-897.
5. Harty TP, Rogawski MA. Felbamate block of recombinant N-methyl- D-aspartate receptors: selectivity for the NR2B subunit. Epilepsy Res. 2000;39(1):47-55.
6. Sitges M, Chiu LM, Guarneros A, Nekrassov V. Effects of carbamazepine, phenytoin, lamotrigine, oxcarbazepine, topiramate and vinpocetine on Na+ channel-mediated release of [3H]glutamate in hippocampal nerve endings. Neuropharmacology. 2007;52(2):598-605.
7. Sitges M, Guarneros A, Nekrassov V. Effects of carbamazepine, phenytoin, valproic acid, oxcarbazepine, topiramate and vinpocetine on the presynaptic Ca2+ channel-mediated release of [3H]glutamate: comparison with the Na+ channel-mediated release. Neuropharmacology. 2007;53(7):854-862.
8. Yang J, Wetterstrand C, Jones RS. Felbamate but not phenytoin or gabapentin reduces glutamate release by blocking presynaptic NMDA receptors in the entorhinal cortex. Epilepsy Res. 2007;77(2-3):157-164.
9. Perucca E. An introduction to antiepileptic drugs. Epilepsia. 2005; 46(Suppl 4):31-37.
10. Gilliam FG. Diagnosis and treatment of mood disorders in persons with epilepsy. Curr Opin Neurol. 2005;18(2):129-133.
11. de Boer HM, Mula M, Sander JW. The global burden and stigma of epilepsy. Epilepsy Behav. 2008;12(4):540-546.
12. Sanchez Alvarez JC, Serrano Castro PJ, Serratosa Fernandez JM. Clinical implications of mechanisms of resistance to antiepileptic drugs. Neurologist. 2007;13(Suppl 1):S38-S46.
13. Luszczki JJ. Third-generation antiepileptic drugs: mechanisms of action, pharmacokinetics and interactions. Pharmacol Rep. 2009;61(2): 197-216.
14. Hiller A, Nguyen N, Strassburg CP, et al. Retigabine N-glucoronidation and its potential role in enterohepatic circulation. Drug Metab Disp. 1999;27(5):605-612.
15. Hermann R, Ferron GM, Erb K, et al. Effects of age and sex on the disposition of retigabine. Clin Pharmacol Ther. 2003:73(1):61-70.
16. Rundfeldt C, Netzer R. Investigations into the mechanism of action of the new anticonvulsant retigabine. Interaction with GABAergic and glutamatergic neurotransmission and with voltage gated ion channels. Arzneimittelforschung. 2000;50(12):1063-1070.
17. Van Rijn CM, Willems-van Bree E. Synergy between retigabine and GABA in modulating the convulsant site of the GABAA receptor complex. Eur J Pharmacol. 2003;464(2-3):95-100.
18. Kapetanovic IM, Yonekawa WD, Kupferberg HJ. The effects of D-23129, a new experimental anticonvulsant drug, on neurotransmitter amino acids in the rat hippocampus in vitro. Epilepsy Res. 1995;22(3):167-173.
19. Brown DA, Passmore GM. Neural KCNQ (Kv7) channels. Br J Pharmacol. 2009;156(8):1185-1195.
20. Rundfeldt C. The new anticonvulsant retigabine (D-23129) acts as an opener of K+ channels in neuronal cells. Eur J Pharmacol. 1997; 336(2-3):243-249.
21. Hetka R, Rundfeldt C, Heinemann U, Schmitz D. Retigabine strongly reduces repetitive firing in rat entorhinal cortex. Eur J Pharmacol. 1999;386(2-3):165-171.
22. Wickenden AD, Yu W, Zou A, Jegla T, Wagoner PK. Retigabine, a novel anti-convulsant, enhances activation of KCNQ2/Q3 potassium channels. Mol Pharmacol. 2000;58(3):591-600.
23. Hempel R, Schupke H, McNeilly PJ, et al. Metabolism of retigabine (D-23129), a novel anticonvulsant. Drug Metab Dispos. 1999;27(5): 613-622.
24. McNeilly PJ, Torchin CD, Anderson LW, Kapetanovic IM, Kupferberg HJ, Strong JM. In vitro glucuronidation of D-23129, a new anticonvulsant, by human liver microsomes and liver slices. Xenobiotica. 1997;27(5):431-441.
25. Ferron GM, Paul J, Fruncillo R, et al. Multiple dose, linear, doseproportional pharmacokinetics of retigabine in healthy volunteers. J Clin Pharmacol. 2002;42(2):175-182.
26. Ferron GM, Patat A, Parks V, Rolan P, Troy SM. Lack of pharmacokinetic interaction between retigabine and phenobarbitone at steady-state in healthy subjects. Br J Clin Pharmacol. 2003;56(1):39-45.
27. Hermann R, Knebel NG, Niebch G, Richards L, Borlak J, Locher M. Pharmacokinetic interaction between retigabine and lamotrigine in healthy subjects. Eur J Clin Pharmacol. 2003;58(12):795-802.
28. Bialer M, Johannessen SI, Kupferberg HJ, Levy RH, Loiseau P, Perucca E. Progress report on new antiepileptic drugs: a summary of Sixth Eilat Conference. Epilepsy Res. 2002;51(1-2):31-71.
29. Mazarati A, Wu J, Shin D, Kwon YS, Sankar R. Antiepileptogenic and antiictogenic effects of retigabine under conditions of rapid kindling: an ontogenic study. Epilepsia. 2008;49(10):1777-1786.
30. Sankar R, Auvin S, Kwon YS, Pineda E, Shin D, Mazarati A. Evaluation of development-specific targets for antiepileptogenic therapy using rapid kindling. Epilepsia. 2010;51(Suppl 3):39-42.
31. Otto JF, Yang Y, Frankel WM, Wilcox KS, White HS. Mice carrying the szt1 mutation exhibit increased seizure susceptibility and altered sensitivity to compounds acting at the m-channel. Epilepsia. 2004; 45(9):1009-1016.
32. Bialer M, Johannessen SI, Levy RH, Perucca E, Tomson T, White HS. Progress report on new antiepileptic drugs: a summary of the Ninth Eilat Conference (EILAT IX). Epilepsy Res. 2009;83(1):1-43.
33. De Sarro G, Di Paola ED, Conte G, Pasculli MP, De Sarro A. Influence of retigabine on the anticonvulsant activity of some antiepileptic drugs against audiogenic seizures in DBA/2 mice. Naunyn-Schmiedeb Arch Pharmacol. 2001;363(3):330-336.
34. Luszczki JJ, Wu JZ, Raszewski G, Czuczwar SJ. Isobolographic characterization of interactions of retigabine with carbamazepine, lamotrigine and valproate in the mouse maximal electroshock-induced seizure model. Naunyn-Schmiedeb Arch Pharmacol. 2009;379(2):163-179.
35. Porter RJ, Partiot A, Sachdeo R, Nohria V, Alves WM; 205 Study Group. Randomized, multicenter, dose-ranging trial of retigabine for partial-onset seizures. Neurology. 2007;68(15):1197-1204.
36. French JA, Abou-Khalil BW, Leroy RF, et al. Randomized, doubleblind, placebo-controlled trial of ezogabine (retigabine) in partial epilepsy. Neurology. 2011;76(18):1555-1563.
37. Brodie MJ, Lerche H, Gil-Nagel A, et al. Efficacy and safety of adjunctive ezogabine (retigabine) in refractory partial epilepsy. Neurology. 2010;75(20):1817-1824.
38. Rostock A, Tober C, Rundfeldt C, et al. (1996) D-23129: a new anticonvulsant with a broad spectrum activity in animal models of epileptic seizures. Epilepsy Res. 1996;23(3):211-223.
39. Zaremba P, Bialek M, Blaszczyk B, Cioczek P, Czuczwar SJ. Non-epilepsy uses of antiepileptic drugs. Pharmacol Rep. 2006;58(1):1-12.
40. Blackburn-Munro G, Jensen BS. The anticonvulsant retigabine attenuates nociceptive behaviours in rat models of persistent and neuropathic pain. Eur J Pharmacol. 2003;460(2-3):109-116.
41. Munro G, Erichsen HK, Mirza NR. Pharmacological comparison of anticonvulsant drugs in animal models of persistent pain and anxiety. Neuropharmacology. 2007;53(5):609-618.
42. Dencker D, Dias R, Pedersen ML, Husum H. Effect of the new antiepileptic drug retigabine in a rodent model of mania. Epilepsy Behav. 2008;12(1):49-53.
43. Hansen HH, Andreasen JT, Weikop P, Mirza N, Scheel-Krüger J, Mikkelsen JD. The neuronal KCNQ channel opener retigabine inhibits locomotor activity and reduces forebrain excitatory responses to the psychostimulants cocaine, methylphenidate and phencyclidine. Eur J Pharmacol. 2007;570(1-3):77-88.
44. Korsgaard MP, Hartz BP, Brown WD, Ahring PK, Strobaek D, Mirza NR. Anxiolytic effects of Maxipost (BMS-204352) and retigabine via activation of neuronal Kv7 channels. J Pharmacol Exp Ther. 2005; 314(1):282-292.
45. Richter A, Sander SE, Rundfeldt C. Antidystonic effects of Kv7 (KCNQ) channel openers in the dt sz mutant, an animal model of primary paroxysmal dystonia. Br J Pharmacol. 2006;149(6):747-753.
46. Surti TS, Jan LY. A potassium channel, the M-channel, as a therapeutic target. Curr Opin Investig Drugs. 2005;6(7):704-711.
47. Gongadze N, Antelawa N, Kezeli T, Okudjava M, Pachkoria K. The mechanisms of neurodegenerative processes and current pharmacotherapy of Alzheimer's disease. Georgian Med News. 2008;155:44-48.
48. Czuczwar SJ, Kaplanski J, Swiderska-Dziewit G, Gergont A, Kroczka S, Kacinski M. Pharmacodynamic interactions between antiepileptic drugs: preclinical data based on isobolography. Expert Opin Drug Metab Toxicol. 2009;5(2):131-136.
49. Stephen LJ, Brodie MJ. Seizure freedom with more than one antiepileptic drug. Seizure. 2002;11(6):349-351.
50. Ebert U, Brandt C, Löscher W. Delayed sclerosis, neuroprotection, and limbic epileptogenesis after status epilepticus in the rat. Epilepsia. 2002;43(Suppl 5):86-95.
51. Boscia F, Annunziato L, Tagliatella M. Retigabine and flupirtine exert neuroprotective actions in organotypic hippocampal cultures. Neuropharmacology. 2006;51(2):283-294.
52. Gao Z, Zhang T, Wu M, et al. Isoform-specific prolongation of Kv7 (KCNQ) potassium channel opening mediated by new molecular determinants for drug-channel interactions. J Biol Chem. 2010;285(36):28322-28332.
53. Blackburn-Munro G, Dalby-Brown W, Mirza NR, Mikkelsen JD, Blacburn-Munro RE. Retigabine: chemical synthesis to clinical application. CNS Drug Rev. 2005;11(1):1-20.
54. Plosker GL, Scott LJ. Retigabine in partial seizures. CNS Drugs. 2006;20(7):601-608.
55. Porter RJ, Nohria V, Rundfeldt C. Retigabine. Neurotherapeutics. 2007;4(1):149-154.
56. Czuczwar P, Wojtak A, Cioczek-Czuczwar A, Parada-Turska J, Maciejewski R, Czuczwar SJ. Retigabine: the newer potential antiepileptic drug. Pharmacol Rep. 2010;62(2):211-219.
57. Owen RT. Ezogabine: a novel antiepileptic as adjunctive therapy for partial onset seizures. Drugs Today. 2010;46(11):815-822.
58. Faught E. Ezogabine: a new angle on potassium gates. Epilepsy Curr. 2011;11(3):75-78.
59. Weisenberg JL, Wong M. Profile of ezogabine (retigabine) and its potential as an adjunctive treatment for patients with partial-onset seizures. Neuropsychiat Dis Treat. 2011;7:409-414.
60. Stafstrom CE, Grippon S, Kirkpatrick P. Ezogabine (retigabine). Nat Rev Drug Discov. 2011;10(10):729-730.
61. Deeks ED. Retigabine (ezogabine): in partial onset seizures in adults with epilepsy. CNS Drugs. 2011;25(10):887-900.
62. Lima Reisser AA, Silva de Lima M, Soares BG, Farrell M. Carbamazepine for cocaine dependence. Cochrane Database Syst Rev. 2009;1:CD002023.
63. Minozzi S, Amata L, Davoli M, et al. Anticonvulsants for cocaine dependence. Cochrane Database Syst Rev. 2008;2:CD006754.
64. Llopis Llacer JJ, Castillo Aquilella A. Efficacy of oxcarbazepine treatment in patients diagnosed with cocaine abuse/dependence. Adicciones. 2008;20(3):263-270. In Spanish.
65. Zullino DF, Khazaal Y, Hattenschwiler J, Borgeat F, Besson J. Anticonvulsant drugs in the treatment of substance withdrawal. Drugs Today. 2004;40(7):603-619.
66. Karila L, Reynaud M, Aubin HJ, et al. Pharmacological treatment for cocaine dependence: is there something new? Curr Pharm Des. 2011; 17(14):1359-1368.
67. Papapetropoulos S, Singer C. Improvement of cervivo-trunco-brachial segmental dystonia with topiramate. J Neurol. 2006;253(4):535-536.
68. Fahn S. Systemic therapy of dystonia. Can J Neurol Sci. 1987; 14(Suppl 3):528-532.
69. Bradbury AJ, Bentick B, Todd PJ. Dystonia associated with carbamazepine toxicity. Postgrad Med J. 1982;58(682):525-526.
70. Richter A, Löschmann PA, Löscher W. The novel antiepileptic drug, lamotrigine, exerts prodystonic effects in a mutant hamster model of generalized dystonia. Eur J Pharmacol. 1994;264(3):345-351.
71. Linazasoro Cristobal G. Efficacy and tolerance of gabapentin in dystonia and hemifacial spasm: a pilot study. Rev Neurol. 2001;33(5):408-410. In Spanish.
72. Pina MA, Modrego PJ. Dystonia induced by gabapentin. Ann Pharmacother. 2005;39(2):380-382.
73. Tekin S, Aykut-Binogöl C, Tanridag T, Aktan S. Antiglutamatergic therapy in Alzheimer's disease - effects of lamotrigine. Short communication. J Neural Transm. 1998;105(2-3):295-303.
74. Mowla A, Pani A. Comparison of topiramate and risperidone for the treatment of behavioral disturbances of patients with Alzheimer's disease: a double-blind, randomized clinical trial. J Clin Psychopharmacol. 2010;30(1):40-43.
75. Ballard C, Corbett A, Chitramohan R, Aarsland D. Management of agitation and aggression associated with Alzheimer's disease: controversies and possible solutions. Curr Opin Psychoatry. 2009;22(6):532-540.
76. Kim Y, Wilkins KM, Tampi RR. Use of gabapentin in the treatment of behavioural and psychological symptoms in dementia: a review of the evidence. Drugs Aging. 2008;25(3):187-196.
77. Sommer OH, Aga O, Cvancarova M, Olsen IC, Selbaek G, Engedal K. Effect of oxcarbazepine in the treatment of agitation and aggression in severe dementia. Dement Geriatr Cogn Disord. 2009;27(2):155-163.
78. Spacey S, Adams P. Familial paroxysmal kinesigenic dyskinesia. In: Pagon RA, Bird TD, Dolan CR, Stephens K, editors. Gene Reviews [Internet]. [Updated March 31, 2011]. Seattle, WA: University of Washington; 1993-2005.
79. Raymond D, Ozelius L. Myoclonus-dystonia. In: Pagon RA, Bird TD, Dolan CR, Stephens K, editors. Gene Reviews [Internet]. [Updated December 19, 2005]. Seattle, WA: University of Washington; 1993-2003.